[go: up one dir, main page]

ZA200109692B - Ziprasidone suspension. - Google Patents

Ziprasidone suspension. Download PDF

Info

Publication number
ZA200109692B
ZA200109692B ZA200109692A ZA200109692A ZA200109692B ZA 200109692 B ZA200109692 B ZA 200109692B ZA 200109692 A ZA200109692 A ZA 200109692A ZA 200109692 A ZA200109692 A ZA 200109692A ZA 200109692 B ZA200109692 B ZA 200109692B
Authority
ZA
South Africa
Prior art keywords
ziprasidone
composition
polysorbate
suspension
chloride
Prior art date
Application number
ZA200109692A
Other languages
English (en)
Inventor
Arenson Daniel Ray
Hong Qi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200109692(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200109692B publication Critical patent/ZA200109692B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
ZA200109692A 1999-05-27 2001-11-26 Ziprasidone suspension. ZA200109692B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
ZA200109692B true ZA200109692B (en) 2002-11-26

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109692A ZA200109692B (en) 1999-05-27 2001-11-26 Ziprasidone suspension.

Country Status (50)

Country Link
EP (1) EP1181018B1 (bg)
JP (1) JP3942827B2 (bg)
KR (1) KR100477782B1 (bg)
CN (1) CN1196486C (bg)
AP (1) AP1409A (bg)
AR (1) AR022643A1 (bg)
AT (1) ATE234097T1 (bg)
AU (1) AU777413B2 (bg)
BG (1) BG65367B1 (bg)
BR (1) BR0010990A (bg)
CA (1) CA2371550C (bg)
CO (1) CO5170458A1 (bg)
CR (1) CR6506A (bg)
CU (1) CU23223B7 (bg)
CZ (1) CZ20014230A3 (bg)
DE (1) DE60001649T2 (bg)
DK (1) DK1181018T3 (bg)
DZ (1) DZ3049A1 (bg)
EA (1) EA003907B1 (bg)
EE (1) EE04704B1 (bg)
ES (1) ES2191618T3 (bg)
GC (1) GC0000190A (bg)
GE (1) GEP20033113B (bg)
GT (1) GT200000081A (bg)
HK (1) HK1046366B (bg)
HN (1) HN2000000071A (bg)
HR (1) HRP20010878B1 (bg)
HU (1) HUP0201297A3 (bg)
IL (2) IL145950A0 (bg)
IS (1) IS2396B (bg)
MA (1) MA26741A1 (bg)
MX (1) MXPA01012124A (bg)
MY (1) MY127891A (bg)
NO (1) NO320296B1 (bg)
NZ (1) NZ514764A (bg)
OA (1) OA11946A (bg)
PA (1) PA8495801A1 (bg)
PE (1) PE20010127A1 (bg)
PL (1) PL196867B1 (bg)
RS (1) RS50089B (bg)
SI (1) SI1181018T1 (bg)
SK (1) SK284590B6 (bg)
SV (1) SV2001000085A (bg)
TN (1) TNSN00112A1 (bg)
TR (1) TR200103392T2 (bg)
TW (1) TWI263498B (bg)
UA (1) UA59491C2 (bg)
UY (1) UY26166A1 (bg)
WO (1) WO2000072847A1 (bg)
ZA (1) ZA200109692B (bg)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． 制御放出ヒドロコドン処方
CN103690540A (zh) 2000-10-30 2014-04-02 欧罗赛铁克股份有限公司 控释氢可酮制剂
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
EP1628973A2 (en) 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005107719A2 (en) 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
HRP20010878B1 (en) 2007-03-31
CR6506A (es) 2004-03-24
BG106153A (bg) 2002-06-28
DE60001649D1 (de) 2003-04-17
PL196867B1 (pl) 2008-02-29
KR100477782B1 (ko) 2005-03-21
HRP20010878A2 (en) 2003-06-30
ATE234097T1 (de) 2003-03-15
EP1181018A1 (en) 2002-02-27
KR20020048307A (ko) 2002-06-22
NO320296B1 (no) 2005-11-21
HN2000000071A (es) 2001-02-02
IL145950A (en) 2007-12-03
SK16782001A3 (sk) 2002-09-10
CA2371550C (en) 2007-01-02
EA200101131A1 (ru) 2002-04-25
CA2371550A1 (en) 2000-12-07
EA003907B1 (ru) 2003-10-30
DZ3049A1 (fr) 2004-03-27
IS2396B (is) 2008-08-15
RS50089B (sr) 2009-01-22
ES2191618T3 (es) 2003-09-16
HUP0201297A3 (en) 2005-09-28
SI1181018T1 (en) 2003-06-30
AU4138500A (en) 2000-12-18
PE20010127A1 (es) 2001-02-06
CU23223B7 (es) 2007-08-30
TNSN00112A1 (fr) 2005-11-10
SV2001000085A (es) 2001-11-08
TR200103392T2 (tr) 2002-11-21
GC0000190A (en) 2006-03-29
PA8495801A1 (es) 2001-12-14
IL145950A0 (en) 2002-07-25
OA11946A (en) 2006-04-13
DE60001649T2 (de) 2003-08-21
HUP0201297A2 (en) 2002-08-28
GT200000081A (es) 2001-11-16
DK1181018T3 (da) 2003-04-22
SK284590B6 (sk) 2005-07-01
CN1196486C (zh) 2005-04-13
HK1046366B (zh) 2005-07-29
MY127891A (en) 2006-12-29
EE200100633A (et) 2003-02-17
NZ514764A (en) 2004-04-30
PL352826A1 (en) 2003-09-08
JP2003500449A (ja) 2003-01-07
BR0010990A (pt) 2002-03-05
AP1409A (en) 2005-06-13
CO5170458A1 (es) 2002-06-27
BG65367B1 (bg) 2008-04-30
EP1181018B1 (en) 2003-03-12
AP2001002346A0 (en) 2001-12-31
NO20015755L (no) 2002-01-23
UY26166A1 (es) 2000-12-29
GEP20033113B (en) 2003-11-25
IS6134A (is) 2001-10-30
MXPA01012124A (es) 2002-06-04
MA26741A1 (fr) 2004-12-20
YU76701A (sh) 2005-07-19
TWI263498B (en) 2006-10-11
NO20015755D0 (no) 2001-11-26
AR022643A1 (es) 2002-09-04
CN1352560A (zh) 2002-06-05
EE04704B1 (et) 2006-10-16
UA59491C2 (uk) 2003-09-15
AU777413B2 (en) 2004-10-14
JP3942827B2 (ja) 2007-07-11
CZ20014230A3 (cs) 2002-08-14
HK1046366A1 (en) 2003-01-10
WO2000072847A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
CA2371550C (en) Ziprasidone suspension
JP2847134B2 (ja) 経口投与用イブプロフェン組成物
KR960012397B1 (ko) 시메티딘을 함유하는 조성물
JP3465820B2 (ja) トロバフロキサシン経口懸濁剤
TWI224004B (en) Pediatric formulation of gatifloxacin
US20070134323A1 (en) Ziprasidone suspension
EP0479777B1 (en) Spironolactone composition
JP2003505421A (ja) ピバリン酸チクソコルトール懸濁液、それをベースとするうがい剤、及びそれを含有するパッケージ